

Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A composition comprising a peptide having the formula R'-Glx-Glx-Lys-R" or a pharmaceutically acceptable salt thereof;

wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 5 and not more than 9 amino acids.

2. (Currently amended) The composition of claim 1, wherein V is H-, Thr-Ala, Thr-Pro-, Ser-Ala-, Ser-Pro-, Ser-Ser-, Met-Leu-Thr-Ala- (SEQ. ID NO.: 1), or Leu-Thr-Ala-; and R" is -H, -Ala, -Ala-Ala or -Ala-~~Val~~ Val.

3. (Currently amended) A composition of claim 2, wherein the peptide is L-Thr-L-~~Pro~~ Pro-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 2).

4. (Currently amended) A composition of claim 2, wherein the peptide is L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 3).

5. (Original) A pharmaceutical preparation comprising:

a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids; and

a physiologically acceptable carrier.

6. (Currently amended) The pharmaceutical preparation of claim 5, wherein V is H-, Glx-, Thr-Ala-Glx, Thr-Pro-Glx-, Ser-Ala-Glx-, Ser-Pro-Glx-, Ser-Ser-Glx-, Met-Leu-Thr-Ala-Glx- (SEQ ID NO.: 4), or Leu-Thr-Ala-Glx- (SEQ. ID NO.: 5); and R" is -H, -Ala, -Ala-Ala or -Ala-Val.

7. (Original) The pharmaceutical preparation of claim 6, wherein the peptide is L-Glu-L-Lys.

8. (Currently amended) The pharmaceutical preparation of claim 6, wherein the peptide is L-Thr-L-Pro-L-Glu-L-Glu-L-Lys (SEQ. ID NO. 2).
9. (Currently amended) A composition of claim 6, wherein the peptide is L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 3).
10. (Original) A method for modulating the activity of a host's immune system, comprising administering to the host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids.
11. (Currently amended) A method as in claim 10, wherein R' is H-, Glx-Thr-Ala-Glx-, Thr-Pro-Glx-, Ser-Ala- ~~Glx~~ Glx-, Ser-Pro-Glx-, Ser-Ser-Glx-, Met-Leu-Thr-Ala-Glx- (SEQ. ID NO.: 4), or Leu-Thr-Ala-Glx- (SEQ. ID NO.: 5); and R" is -H, -Ala, -Ala-Ala or -Ala-Val.
- 12 (Currently amended) A method as in claim 11, wherein the peptide is L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 3) or L-Glu-L-Lys.
13. (Original) A method as in claim 10, wherein the peptide is administered in a physiologically acceptable carrier.
14. (Original) A method for treating an infection in a host, comprising administering to the host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; V is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids.
15. (Currently amended) The method as in claim 14, wherein R' is H-, Glx-, Thr-Ala-Glx-, Thr-Pro-Glx-, Ser-Ala-Glx-, Ser-Pro-Glx-, Ser-Ser-Glx-; Met-Leu-Thr-Ala-Glx- (SEQ. ID NO.: 4), or Leu-Thr-Ala-Glx- (SEQ. ID NO.: 5); and R" is -H, -Ala, -Ala-Ala or -Ala-Val.
16. (Currently amended) The method as in claim 14, wherein the peptide is L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 3) or L-Glu-L-Lys.
17. (Original) The method as in claim 14, wherein the infection is a bacterial

infection.

18. (Original) The method as in claim 17, further comprising administering an antibiotic to the host.

19 (Original) The method as in claim 14, wherein the infection is a viral infection.

20. (Original) The method as in claim 19, further comprising administering an antiviral agent to the host.

21. (Original) The method as in claim 14, wherein the infection is a fungal infection.

22. (Original) The method as in claim 21, further comprising administering an antifungal agent to the host.

23. (Original) The method as in claim 14, wherein the infection is a parasitic infection.

24. (Original) The method as in claim 23, further comprising administering an antiparasitic agent to the host.

25. (Original) The method as in claim 14, wherein the peptide is administered intravenously, intramuscularly, intrathecally, subcutaneously, intraperitoneally, intranasally, orally, intrabronchially, rectally, or topically.

26. (Original) A method for treating atopic states in a host comprising administering to the host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gin; TV is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids.

27. (Currently amended) The method as in claim 26, wherein R' is H-, Glx-, Thr-Ala-Glx-, Thr-Pro-Glx-, Ser-Ala-Glx, Ser-Pro-Glx-, Ser-Ser-Glx-, Met-Leu-Thr-Ala-Glx- (SEQ. ID NO.: 4), or Leu-Thr-Ala-Glx- (SEQ. ID NO.:5); and R" is -H, -Ala, -Ala-Ala or -Ala-Val.

28. (Currently amended) The method as in claim 27, wherein the peptide is L-Thr-L-Ala-L-Glu-L-Glu-L-Lys (SEQ. ID NO.: 3) or L-Glu-L-Lys.

29. (Original) A method of treating leukocytic disorders in a host comprising administering to the host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; TV is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids.

30. (Original) A method for augmenting vaccinations in a host comprising administering to the host a peptide having the formula R'-Glx-Lys-R" or a pharmaceutically acceptable salt thereof, wherein Glx is Glu or Gln; R' is H- or a first amino acid sequence having fewer than 7 amino acids; R" is -H or a second amino acid sequence having fewer than 7 amino acids; and the peptide has a sequence of at least 2 and not more than 9 amino acids.